Diagnos is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its artificial intelligence tool CARA (computer-assisted retina analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA is a cost-effective tool for screening large numbers of patients in real time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.

1. WHERE AI BECOMES REALITY.

2. www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved
This document contains certain forward-looking statements with respect to the
Corporation. These forward-looking statements, by their nature, necessarily involve
risks and uncertainties that could cause actual results to differ materially from those
contemplated by these forward-looking statements. We consider the assumptions on
which these forward-looking statements are based to be reasonable, but caution the
reader that these assumptions regarding future events, many of which are beyond our
control, may ultimately prove to be incorrect since they are subject to risks and
uncertainties that affect us. These risks and uncertainties include risks associated with
market acceptance, competitive developments and other factors. Except for ongoing
obligations under securities laws to disclose all material information to investors, we
disclaim any intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Disclaimer

3. www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved
AGENDA
Presentations
1. Market Opportunity
2. Sales and Marketing Overview
3. Financial Overview

4. MARKET OPPORTUNITY 1

5. DIABETES
CANADA
In 2017: Total Healthcare $242 Billion
5,000$ per diabetic per year
(Source: Canadian Diabetes Association. The Prevalence and Costs of Diabetes)
USA
In 2016: Total Healthcare $5 trillion
327 billion US $ per year (2017)/42 million diabetics=
7,785$ per diabetic per year

6. DIABETES
Worldwide
The global cost of diabetes is now 825 billion dollar
according to the largest ever study of diabetes levels
across the world. (The Lancet Diabetes &
Endocrinology Study)
Number of people with diabetes has risen from 108
million in 1980, to 422 million in 2014. (WHO)
Source: WHO 2016

7. CARDIOVASCULAR
CANADA
CVD costs the Canadian economy more than $20.9
Billion every year. Source: The Conference Board of Canada
20.9 billion $/ 1,322,500 = 15 803.40 $ per adults that
have coronary heart disease per year
USA
315 billions US $ per year
21,000$ per adults that have coronary heart disease, per
year

8. CARDIOVASCULAR
Worldwide
By 2035, cardiovascular diseases will be the most
costly and prevalent killer (if left unchecked), and
will place a crushing economic and health burden
on the nation's financial and health care systems.
(Study conducted by RTI International for the
American Heart Association.)
By 2030, the total global cost of CVD is set to rise
from approx. US$863 billion in 2010, to a
staggering US$1,044 billion.
(Source: World Heart Federation)

9. www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved
Per Patient Economics
DIAGNOS keeps ~50% of its healthcare billings for handling all screenings procedures, reporting, data storage, and
regulatory compliances.
Healthcare
Professional
Patients Insurance Provider
Patient’s Medical Information
CARA CARA-HT
Diagnos

10. DIAGNOS’ OPPORTUNITY
DIABETES: 2% of market * 8.4B=168M $ US
CARDIO: 2% of market * 950 B=19B $ US
HYPERTENSION: 2% of market*450B=9B $ US

11. SALES AND MARKETING
OVERVIEW
2

12. www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved
Artificial intelligence market.
• AI in healthcare aims to improve patient outcomes by
assisting healthcare practitioners in using medical
knowledge.
• The AI market for healthcare applications is expected to
achieve rapid adoption globally, with a compound annual
growth rate (CAGR) of 42 percent until 2021.
• By 2020, chronic conditions such as cancer and diabetes are
expected to be diagnosed in minutes using cognitive
systems.
• By 2025, AI systems are expected to be implemented in 90
percent of the US and 60 percent of the global hospitals and
insurance companies.

13. Diabetes. A global emergency.
2015 and 2040 (20-79 years)
Europe
2015 – 59.8 million
2040 – 71.1 million
North America & Caribbean
2015 – 43.3 million
2040 – 60.5 million
South & Central America
2015 – 29.6 million
2040 – 48.8 million
Middle East & North Africa
2015 – 35.4 million
2040 – 72.1 million
Africa
2015 – 14.2 million
2040 – 34.2 million
South East Asia
2015 – 78.3 million
2040 – 140.2 million
Western Pacific
2015 – 153.2 million
2040 – 214.8 million
WORLD
2015 – 415 million
2040 – 642 million

14. The Global Burden of Cardiovascular Disease, American College of Cardiology 2017 Source: WHO

15. Multi National Program.

16. www.diagnos.ca
© 2017 | Diagnos inc. All Right Reserved
Shifting industry landscape creating
opportunities for growth
1. Diagnos offers a tailored solution to the public and parapublic organizations (Governments)
2. Management has over 50 years of combined experience working on artificial intelligence in the tech, science, and healthcare
space.
3. The AI market for healthcare applications is expected to achieve rapid adoption globally, with a compound annual growth rate
(CAGR) of 42% until 2021.
4. By 2020, chronic conditions such as cancer and diabetes are expected to be diagnosed in minutes using cognitive systems.
5. Their proprietary technology CARA, integrates with almost an type of camera allowing a seamless automation of detection of
pathology in retinal photographs.
QUOTE TSK-V: ADK
QUOTE OTCQB: GNOF

17. www.diagnos.ca
© 2017 | Diagnos inc. All Right Reserved
Competitive advantage
Analysis of multiple pathology with same hardware (camera)
1. Retinal CARA (2017)
1. CARA-HT (July 2018)
1. CARA CARDIO ( 2019 )
More than one application using the medical imaging of
the retina.

18. www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved
ISO 9001 : 2008
ISO 13485 : 2003
CMDCAS
HEALTH CANADA
FDA
CE MARK
Regulatory Compliance
CERTIFIED
CERTIFIED
CERTIFIED
APPROVED
APPROVED
APPROVED
Class 2 Medical Device
Class 2 Medical Device
510K
(1) Canadian Medical Devices Conformity
Assessment System
(1)

19. www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved
Telemedicine / Referral Pathway
• Tele-ophthalmology platform
• Integrates with almost any camera
• Comprises image upload, automated, pre-screening, grading
and referral interface
• Modules extend functionality
• Enhancement
• Automated pre-Analysis (DR)
• Automated pre-Analysis (other)
Client/Patient Camera
Operator
PACS PC
Intepreter
Doctor
Secure internet
connection
Camera

20. www.diagnos.ca
© 2018| Diagnos inc. All Right Reserved
Severe Diabetic Retinopathy.
Severe Diabetic Retinopathy DIAGNOS Enhanced
• Severe Diabetic Retinopathy may
lead to blindness and may or may
not have symptoms
• It is very important to see a retina
specialist as soon as possible to
discuss treatment options
• The earlier the treatment is started,
the better the outcome

21. www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved
Automatic Detection and Triage
(Diabetic Retinopathy)
Our algorithms are capable of :
• Automatic detection of pathology in retinal photographs
• Lesion classification
• Pre-triaging patients in order of severity
Automated triage can help reduce
healthcare labour requirements while
increasing patient access to quality care
and reducing healthcare expenditure

22. www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved
Automatic Detection and Triage
(Hypertension Retinopathy)
Our algorithms are capable of :
• Automatic detection of pathology in retinal photographs
• Lesion classification
• Pre-triaging patients in order of severity
Automated triage can help reduce
healthcare labour requirements while
increasing patient access to quality care
and reducing healthcare expenditure

23. www.diagnos.ca
© 2017 | Diagnos inc. All Right Reserved
CARA - CARDIO

24. www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved
Deployment Options
We are flexible with regards to our screening options
● Mobile ($$$$)
● Managed ($$$)
● Standalone ($$)
● Software only ($)

25. Value proposition.
• Patient : Convenient non-invasive test & trip to specialist
only if necessary.
• Diabetologist/GP/Endo : Higher patient compliance &
additional pertinent patient information
• Retina Specialist : Increased focus on treatable cases
& increased revenue.
• Pharmaceutical Company : Increased drug sales
volume
• Insurance Company : Increased patient compliance &
decreased health plan expenditure
• Government : Significant cost avoidance mid/long term
& positive political optics

26. FINANCIAL OVERVIEW 3 Outline:
● 2017-2018 recap
● 2019-2021 outlook
● Capital Allocation

27. www.diagnos.ca
Executing on our strategic drivers.
© 2018 | Diagnos inc. All Right Reserved
OBJECTIVES
1. Volume growth in number of patients screened
2. Return on capital
3. Growth in the market share
4. Increase share value

28. Revenue Growth Plan
Management will focus on three core pillars of revenue growth to drive shareholder value:
2
Novartis
Walgreens Boots Alliance
Others
Pharmaceutical
1
IMSS
OthersGovernment
3
Private clinics
Wellness organs
Others
Private Sectors
Current % of Revenue Goal as % of
Revenue
50%
25%
25%
www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved

29. Market Statistics
Trading Symbol (ADK.v)
Share Price (As at 09-08-18) $0.06
52 Week High – Low $0.16 - $0.05
Number of Shares Outstanding 173,221,265
Number of Stock Options 16,122,684
Number of Conversion Options 46,950,000
Number of Warrants 9,420,000
Fully diluted number of Shares 245,713,949
Market Cap.
$10.4M - undiluted
$14.7M - fully diluted
Insider Ownership (%) 2%
www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved

30. www.diagnos.ca
© 2018 | Diagnos inc. All Right Reserved
Financial Highlights
Year ended March 31,
2017 2018 2019 2020 2021
Actual Forecast
($'000)
Revenue $2,390 $1,613 $3,700 $7,000 $10,500
COGS (432) (510) (700) (1,400) (2,600)
Operating expenses (3,846) (3,339) (3,500) (3,900) (4,300)
EBITDA ($1,888) ($2,236) ($500) $1,700 $3,600
Depreciation ($194) ($230) (300) (300) (300)
Interest expense ($955) ($828) (400) - -
Other $107 $397 - - -
Net (loss) profit ($2,930) ($2,897) ($1,200) $1,400 $3,300
Cash $189 $150 ($750) $950 $4,550

31. André Larente
President, CEO, DIAGNOS inc.
alarente@diagnos.com
+ 1 (450) 678-8882, Ext. 224
Corporation’s office
Suite 340, 7005 Taschereau Blvd.
Brossard, Quebec, J4Z 1A7, Canada
info@diagnos.com
TSXV : ADK.V
OTCQB : DGNOF
Marc-André Massue
VP - Finances
Guillermo Moreno Robles
VP - Sales
Yves-Stéphane Couture
VP - Sales
Hadi Chakor
Chief Medical Officer